Critical Reviews in Oncology Hematology

Critical Reviews in Oncology/Hematology is a peer-reviewed review journal founded in 1983 and published by Elsevier, serving as an official journal of the European School of Oncology and the International Society of Liquid Biopsy, with a 2025 Journal Impact Factor of 6.2《肿瘤学与血液学评论》（Critical Reviews in Oncology/Hematology）是 1983 年创刊、（Elsevier）出版的同行评审综述期刊，为欧洲肿瘤学院与国际液体活检学会的官方期刊，2025 年影响因子为 6.2。

Scope

• The journal publishes scholarly, critical reviews in all fields of oncology and hematology, written by experts from around the world该刊刊载由世界各地专家撰写的学术性批判综述，覆盖肿瘤学与血液学的全部领域。
• Thirteen themes are listed, from basic experimental oncology, clinical research and hematology through immunotherapy, radiotherapy and surgery官方列出十三大主题，从基础实验肿瘤学、临床研究与血液学到免疫治疗、放疗与外科。
• Molecular pathology, genomics, omics and liquid biopsy form one dedicated theme, aligning the journal with the International Society of Liquid Biopsy分子病理学、基因组学、组学与液体活检构成专门主题，使该刊与国际液体活检学会相呼应。
• Career development and education in oncology, palliative support, and regulatory, ethics and health policy questions also fall within its remit肿瘤学职业发展与教育、姑息支持以及监管、伦理与卫生政策问题亦属其范围。
• Pediatric oncology, solid tumors, statistics, meta-analysis and clinical trial design complete the theme list儿科肿瘤学、实体瘤、统计学、荟萃分析与临床试验设计补全了主题清单。
• All reviews are subject to peer review所有综述均须经同行评审。
• In the Journal Citation Reports the journal ranks 15th of 103 in hematology and 60th of 333 in oncology, both in the first quartile在《期刊引证报告》中，该刊在血液学类 103 种期刊中列第 15 位、在肿瘤学类 333 种期刊中列第 60 位，均居第一分区。

History

• The journal began with volume 1 in January 1983, its first issue carrying an editorial board statement该刊于 1983 年 1 月以第 1 卷起步，创刊号载有编委会声明。 ^[1]
• The founding editor Stephen Davis wrote the foreword in that first issue创刊主编（Stephen Davis）在创刊号撰写了发刊词。 ^[2]
• It is an official journal of the European School of Oncology and of the International Society of Liquid Biopsy该刊是欧洲肿瘤学院与国际液体活检学会的官方期刊。
• By December 2026 the journal had reached volume 228至 2026 年 12 月，该刊已出版至第 228 卷。
• Its print ISSN is 1040-8428 and its electronic ISSN is 1879-0461其印刷版 ISSN 为 1040-8428，电子版 ISSN 为 1879-0461。
• Its Journal Impact Factor moved from 6.312 in 2021 through 6.625 in 2022 and 5.6 in 2024 to 6.2 in 2025其影响因子由 2021 年的 6.312 经 2022 年的 6.625 与 2024 年的 5.6 至 2025 年的 6.2。

Editors

• The Editor-in-Chief is Christian Rolfo, MD, PhD, MBA, of the Ohio State University Comprehensive Cancer Center in Columbus主编为（Christian Rolfo）医学博士、哲学博士、工商管理硕士，任职于哥伦布的俄亥俄州立大学综合癌症中心。
• In late 2021 he was listed at the Icahn School of Medicine at Mount Sinai in New York, moving to Ohio thereafter2021 年末他还列名于纽约西奈山伊坎医学院，其后转赴俄亥俄。
• The editorial board counted 84 members in the 2026 listing, spread across 21 countries2026 年名单中编委会共有 84 位成员，分布于 21 个国家。
• The United States contributes 21 members and Italy 19, followed by Switzerland with 8, Canada with 6, France with 5, and Germany and the Netherlands with 4 each其中美国 21 位、意大利 19 位，其后为瑞士 8 位、加拿大 6 位、法国 5 位、德国与荷兰各 4 位。
• The board is organised in five tiers: the Editor-in-Chief, deputy editors, associate editors, honorary editors and the editorial board编委会分为五层：主编、副主编、领域副主编、荣誉编辑与编委会成员。
• Further members are based in Japan, Slovenia, Spain, Turkey, Saudi Arabia, Colombia, the United Kingdom, Singapore, Russia, Denmark, Israel, Portugal, Greece and Belgium其余编委分驻日本、斯洛文尼亚、西班牙、土耳其、沙特阿拉伯、哥伦比亚、英国、新加坡、俄罗斯、丹麦、以色列、葡萄牙、希腊与比利时。